首页> 外文OA文献 >Treatment of Proximal Deep-Vein Thrombosis with the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) Study

【2h】

Treatment of Proximal Deep-Vein Thrombosis with the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) Study

机译：口服直接因子Xa抑制剂利伐沙班治疗近端深静脉血栓形成（BAY 59-7939）：ODIXa-DVT（急性症状性深静脉血栓形成患者的口服直接因子Xa抑制剂BAY 59-7939）研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Agnelli G.; Gallus A.; Goldhaber S.Z.;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. [J] . Eriksson BI, Borris LC, Dahl OE, Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis . 2007,第5期

机译：利伐沙班（BAY 59-7939）的剂量递增研究-口服直接Xa因子抑制剂-预防全髋关节置换患者的静脉血栓栓塞。
2. Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen [J] . Dagmar Kubitza, Michael Becka, Wolfgang Mueck, British journal of clinical pharmacology . 2007,第4期

机译：利伐沙班（BAY 59-7939）–口服直接Xa因子抑制剂–与萘普生无临床相关相互作用
3. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. [J] . Kubitza D, Becka M, Zuehlsdorf M, The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2006,第5期

机译：食物，抗酸剂和H2拮抗剂雷尼替丁对健康受试者中口服直接Xa抑制剂BAY 59-7939（利伐沙班）吸收的影响。
4. Andexanet alfa for reversal of factor Xa inhibitors induced-anticoagulation in nonclinical and clinical studies [C] . Genmin Lu, Polly Pine, Janet Leeds, World biomaterials congress . 2016

机译：Andexanet alfa在非临床和临床研究中逆转Xa因子抑制剂诱导的抗凝作用
5. A new mechanism-driven bypassing strategy for direct factor Xa inhibitors reveals an unexpected property of target specific anticoagulants. [D] . Thalji, Nabil K. 2015

机译：直接因子Xa抑制剂的新机制驱动旁路策略揭示了靶标特异性抗凝剂的出乎意料的特性。
6. Rivaroxaban (BAY 59-7939) – an oral direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen [O] . Dagmar Kubitza, Michael Becka, Wolfgang Mueck, 2007

机译：利伐沙班（BAY 59-7939）–口服直接Xa因子抑制剂–与萘普生无临床相关相互作用
7. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study [O] . Goldhaber, Samuel Z, Haas, Sylvia, Huisman, Menno V, 2007

机译：中医治疗近端深静脉血栓形成口服直接因子Xa抑制剂利伐沙班（BAY 59-7939）：ODIXa-DVT（口服直接因子Xa抑制剂BAY 59-7939在急性症状性深静脉患者中的应用血栓形成）研究

Treatment of Proximal Deep-Vein Thrombosis with the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) Study

著录项

相似文献

相关主题

期刊订阅